Follicular lymphoma · 4 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Obinutuzumab monotherapy Variant #03 | — | R 166 941 | 21d | — | — | — | — | — |
Bendamustine and Obinutuzumab Variant #02 | — | R 106 233 | 28d | — | — | — | — | 2 |
Ibritumomab tiuxetan protocol Variant #18 | — | R 27 524 | 8d | ~36.5 mo | — | ~139 | ~R 3 825 804 PFS proxy · indirect | 1 |
Bendamustine monotherapy Variant #01 | — | R 5 419 | — | ~16.5 mo | — | — | — | 2 |
4 of 4 regimens shown